23
total announcements
532305.BO · 15 min delayed
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has responded to BSE Surveillance's query regarding the sudden increase in volume of its shares, stating that the company has made all necessary disclosures and is not aware of any specific reason for the spurt in volume/price.
Ind-Swift Laboratories Ltd
The BSE has sought clarification from Ind-Swift Laboratories Ltd regarding a movement in volume on August 27, 2026, and is awaiting a response.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has announced its Q1 FY27 earnings, with a strong quarter of performance, both operationally and financially. The company has commercialized new products, expanded its CDMO partnerships, and seen growth in its export business.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd announced that it will upgrade its Jammu facility to EU-GMP and PICS compliant standards, targeting additional revenue of 100 crores from 2029-30 onwards. The facility will cater to the European and other regulated markets, and the total planned investment is around Rs. 45 crores.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has made available the audio recording of its earnings conference call held on August 17, 2026, to discuss its financial results for the quarter ended June 30, 2026. The transcript will be shared with stock exchanges and uploaded on the company's website.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with a strong operating EBITDA improving 2.85x YoY to ₹33.32 crore and op. EBITDA margin expanding by 1,258 bps YoY to 17.91%. The company has also commercialized its Viatris (Ireland, Europe), Manx (UK) and Arrotex (Australia) CDMO Partnerships/Own-Brands, expected to contribute an incremental ₹200-220 crore of revenue in FY27.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has announced a conference call to discuss its Q1 FY 2026-27 financial results, scheduled for August 17, 2026.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI Regulations, for the utilization of proceeds from the preferential issue. The report has been reviewed by the Audit Committee and taken on record by the Board.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd reported strong Q1 FY27 results with operating EBITDA up 2.85x YoY to ₹33.32 crore and PAT up 2.04x YoY to ₹24.68 crore, driven by growing international operations and expansion across regulated and emerging markets.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, and approved the sale of land for ₹17.50 Crore. The company has also disclosed its standalone and consolidated un-audited financial results, along with the limited review report of the statutory auditors.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has filed a statement of nil deviation for the quarter ended June 30, 2026, confirming that there is no deviation or variation in the use of funds raised through the preferential issue of convertible warrants.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has announced its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, and approved the sale of land for ₹17.50 Crore. The company has also disclosed its limited review reports issued by the statutory auditors.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has informed about the amendments to its Memorandum & Articles of Association, approved by shareholders through a Special Resolution dated August 5, 2026.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd held an Extra-Ordinary General Meeting (EGM) on August 5, 2026, where three resolutions were passed with the requisite majority. The resolutions included the issuance of up to 70,00,000 fully convertible warrants to an entity belonging to the promoter and promoter group on a preferential basis, the re-appointment of Sh. Rajinder Kumar Gupta as an Independent Director for a second term of five years, and the alteration of Article of Association by substitution of Article 76.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd held its 1st Extra-Ordinary General Meeting (EGM) on August 5, 2026, through video conferencing, where 52 shareholders participated. The meeting approved two special business resolutions: issuance of up to 70,00,000 fully convertible warrants to an entity belonging to the promoter and re-appointment of an independent director.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has announced a Special Window for re-lodgement of transfer requests of physical shares and dematerialisation, in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated January 30, 2026.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on August 10, 2026, to consider and approve Un-Audited Financial Results for the quarter ended June 30, 2026.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has issued a corrigendum to the notice of its Extra-Ordinary General Meeting (EGM) scheduled to be held on August 05, 2026. The corrigendum makes changes to the explanatory statement regarding the proposed preferential issue of 70,00,000 fully convertible warrants to an entity belonging to the promoter and promoter group. The changes pertain to the objects of the preferential issue, including expansion of business, research and development, technology upgradation, and investment in a subsidiary.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has informed that the Preferential Issue Committee of the Board of Directors has approved the Corrigendum to the EGM Notice dated July 29, 2026, convening the Extraordinary General Meeting of the Company scheduled to be held on August 05, 2026, to seek approval for the proposed Preferential Issue of Fully Convertible Warrants.
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd has entered into a Memorandum of Understanding (MOU) with Him Infratech Private Limited for the construction of a warehouse facility at the company's leasehold land in Punjab. The estimated contract cost is approximately ₹40 Crore. The warehouse is expected to strengthen the company's storage and logistics infrastructure and improve operational efficiencies.